Inhibrx Biosciences, Inc. (INBX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.14B
Last updated: Nov 17, 2026 at 4:15 PM ET
Inhibrx Biosciences, Inc. (INBX) Statistics
Inhibrx Biosciences (INBX) has a market cap of $1.14B and an enterprise value of $1.22B. It kept -7082.90% of revenue as net income over the last 12 months. Revenue grew 42.86% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 6.76% above the market cap, as debt exceeds cash.
| Market Cap | $1.14B |
|---|---|
| Enterprise Value | $1.22B |
| Latest price (Nov 17, 2026) | $74.18 |
Key Dates
The next earnings report is expected on Mar 17, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 17, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 6.26% over 52 weeks and trades 20.74% below its 50-day average.
| Beta (1Y) | 2.17 |
|---|---|
| 52-Week Change | -6.26% |
| 1-Month Change | -17.39% |
| 3-Month Change | -26.90% |
| 6-Month Change | -32.26% |
| Total Return (1Y) | -6.26% |
| Return vs SPY (1Y) | -15.95% |
| Max Drawdown (1Y) | -49.39% |
| Max Drawdown (3Y) | -49.39% |
| Sharpe Ratio (1Y) | -0.06 |
| Correlation with SPY (1Y) | 0.37 |
| 50-Day Average | $93.59 |
| 200-Day Average | $92.66 |
| 52-Week Range | $57.30 to $155.29 |
| RSI (14 Days) | 38.2 |
| Average Volume (20 Days) | 313.72K |
Financial Position
Current assets cover 7.58x current liabilities.
| Current Ratio | 7.58x |
|---|---|
| Quick Ratio | 7.58x |
| Interest Coverage | 125.28x |
Returns and Efficiency
Return on invested capital is -65.95% over the last 12 months.
| Return on Assets (ROA) | -64.30% |
|---|---|
| Return on Invested Capital (ROIC) | -65.95% |
| Return on Capital Employed (ROCE) | -65.21% |
| Asset Turnover | 0.01x |
| Receivables Turnover | 12.05x |
Scores
INBX has an Altman Z-Score of -0.87, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.87 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $2.00M over the last 12 months.
| Revenue | $2.00M |
|---|---|
| Revenue Growth (YoY) | +42.86% |
| Gross Profit | $1.44M |
| Operating Income | -$125.73M |
| Pretax Income | -$141.66M |
| Net Income | -$141.66M |
| EBITDA | -$118.90M |
| EBIT | -$125.85M |
| Reported EPS (TTM) | -$9.06 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $199.47M |
|---|---|
| Total Debt | $276.70M |
| Net Debt | $77.23M |
| Net Debt Per Share | $4.91 |
| Working Capital | $179.57M |
| Shareholder Equity | -$85.88M |
| Total Assets | $220.29M |
| Total Liabilities | $306.17M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$132.67M |
|---|---|
| FCF Per Share | -$9.02 |
| Depreciation and Amortization | $6.95M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -6286.70%.
| Gross Margin | 71.80% |
|---|---|
| Operating Margin | -6286.70% |
| Pretax Margin | -7082.75% |
| Net Margin | -7082.90% |
| EBITDA Margin | -5945.00% |
| EBIT Margin | -6292.50% |
Growth
Revenue fell 15.98% a year over 3 years.
| Revenue Growth (3Y CAGR) | -15.98% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | -19.93% |
| Tangible Book Per Share Growth (2Y CAGR) | -19.93% |
Peer Position
Against 6 similar companies, INBX has the highest P/S.
P/S RatioPeer median 4.1x
ROICPeer median -18.68%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -43.59%
| P/S Ratio | 583.1x vs 4.1x median |
|---|---|
| ROIC | -65.95% vs -18.68% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +42.86% vs -43.59% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About INBX
What is INBX's market cap?
Inhibrx Biosciences has a market cap of $1.14B. Its enterprise value, which adds debt and subtracts cash, is $1.22B.
How many shares of INBX are outstanding?
Inhibrx Biosciences has 15.72M shares outstanding. The count is up 1.56% from a year earlier.
Does INBX pay a dividend?
No. Inhibrx Biosciences does not pay a dividend.
How much debt does INBX have?
Inhibrx Biosciences has $276.70M of total debt and $199.47M of cash and equivalents, a net debt position of $77.23M.
INBX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors